Cargando…

Assessing the accuracy of [(18)F]PSMA-1007 PET/CT for primary staging of lymph node metastases in intermediate- and high-risk prostate cancer patients

BACKGROUND: [(18)F]PSMA-1007 is a promising tracer for integrated positron emission tomography and computed tomography (PET/CT). OBJECTIVE: Our aim was to assess the diagnostic accuracy of [(18)F]PSMA-1007 PET/CT for primary staging of lymph node metastasis before robotic-assisted laparoscopy (RALP)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ingvar, Jacob, Hvittfeldt, Erland, Trägårdh, Elin, Simoulis, Athanasios, Bjartell, Anders
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9363552/ https://www.ncbi.nlm.nih.gov/pubmed/35943665 http://dx.doi.org/10.1186/s13550-022-00918-7

Ejemplares similares

Freely available artificial intelligence for pelvic lymph node metastases in PSMA PET-CT that performs on par with nuclear medicine physicians
por: Trägårdh, Elin, et al.
Publicado: (2022)

Biokinetics and dosimetry of (18)F‐PSMA‐1007 in patients with prostate cancer
por: Hvittfeldt, Erland, et al.
Publicado: (2022)

PET/CT imaging 2 h after injection of [(18)F]PSMA-1007 can lead to higher staging of prostate cancer than imaging after 1 h
por: Hvittfeldt, Erland, et al.
Publicado: (2023)

Freely Available, Fully Automated AI-Based Analysis of Primary Tumour and Metastases of Prostate Cancer in Whole-Body [(18)F]-PSMA-1007 PET-CT
por: Trägårdh, Elin, et al.
Publicado: (2022)

Dose-reduced [(18)F]PSMA-1007 PET is feasible for functional imaging of the renal cortex
por: Valind, Kristian, et al.
Publicado: (2021)

FDG-PET/CT for lymph node staging prior to radical cystectomy
por: Pihl, Vilhelm, et al.
Publicado: (2023)

Optimization of [(18)F]PSMA-1007 PET-CT using regularized reconstruction in patients with prostate cancer
por: Trägårdh, Elin, et al.
Publicado: (2020)

[(18)F]PSMA-1007 PET is comparable to [(99m)Tc]Tc-DMSA SPECT for renal cortical imaging
por: Valind, Kristian, et al.
Publicado: (2023)

Diagnostic Accuracy of (18)F-PSMA-1007 PET/CT Imaging for Lymph Node Staging of Prostate Carcinoma in Primary and Biochemical Recurrence
por: Sprute, Katharina, et al.
Publicado: (2021)

Detection of lymph node metastases in patients with prostate cancer: Comparing conventional and digital [(18)F]‐fluorocholine PET‐CT using histopathology as a reference
por: Bjöersdorff, Mimmi, et al.
Publicado: (2022)

[(18)F]PSMA‐1007 renal uptake parameters: Reproducibility and relationship to estimated glomerular filtration rate
por: Valind, Kristian, et al.
Publicado: (2022)

Heterogeneous uptake of (18)F-FDG and (18)F-PSMA-1007 PET/CT in lung cancer and lymph node metastasis
por: Hu, Yuan, et al.
Publicado: (2023)

Impact of non-regional lymph node metastases accurately revealed on (18)F-PSMA-1007 PET/CT in the clinical management of metastatic hormone-sensitive prostate cancer
por: Jiang, Zhangdong, et al.
Publicado: (2023)

Diagnostic accuracy of [(18)F]PSMA-1007 PET/CT in biochemical recurrence of prostate cancer
por: Mingels, Clemens, et al.
Publicado: (2022)

Isolated Rectal Metastases from Locally Advanced Carcinoma Prostate Detected by (18) F-PSMA-1007 PET/CT
por: Singh, Shashank Shekhar, et al.
Publicado: (2022)

Accuracy of (68)Ga-PSMA PET-CT and PET-MRI in lymph node staging for localized prostate cancer
por: Barbosa, Álan Roger Gomes, et al.
Publicado: (2022)

PSMA-Positive Low Malignant Gastrointestinal Stromal Tumor in the Stomach on F-18-PSMA-1007 PET/CT
por: Iversen, Peter, et al.
Publicado: (2022)

Multiparametric dynamic whole-body PSMA PET/CT using [(68)Ga]Ga-PSMA-11 and [(18)F]PSMA-1007
por: Dias, André H., et al.
Publicado: (2023)

PSMA PET for primary lymph node staging of intermediate and high-risk prostate cancer: an expedited systematic review
por: Petersen, Lars J., et al.
Publicado: (2020)

(18)F-PSMA-1007 PET/CT Performance on Risk Stratification Discrimination and Distant Metastases Prediction in Newly Diagnosed Prostate Cancer
por: Wang, Zhuonan, et al.
Publicado: (2021)

(18)F-PSMA-1007 PET/CT uptake in multiple angiolipomas caused by PSMA expression in capillaries: a case report
por: Wang, Long, et al.
Publicado: (2021)

Non-prostate uptake on (18)F-PSMA-1007 PET/CT: a case of myeloma
por: Veerasuri, Sowmya, et al.
Publicado: (2020)

(18)F-PSMA-1007 PET in Biochemical Recurrent Prostate Cancer: An Updated Meta-Analysis
por: Ferrari, Matteo, et al.
Publicado: (2021)

Primary Staging of Prostate Cancer Patients with [(18)F]PSMA-1007 PET/CT Compared with [(68)Ga]Ga-PSMA-11 PET/CT
por: Hoffmann, Manuela A., et al.
Publicado: (2022)

Gross tumor volume delineation in primary prostate cancer on (18)F-PSMA-1007 PET/MRI and (68)Ga-PSMA-11 PET/MRI
por: Zhang, Yan-Nan, et al.
Publicado: (2022)

Mesorectal Lymph Node Metastases as Index Lesion in (68)Ga-PSMA-PET/CT Imaging for Recurrent Prostate Cancer
por: Leitsmann, Conrad, et al.
Publicado: (2021)

Cribriform pattern disease over‐represented in pelvic lymph node metastases identified on (68)GA PSMA‐PET/CT
por: Bolton, Damien, et al.
Publicado: (2022)

Meta-analysis of (18) F-PSMA-1007 PET/CT, (18) F-FDG PET/CT, and (68)Ga-PSMA PET/CT in diagnostic efficacy of prostate Cancer
por: Yu, Wenxiao, et al.
Publicado: (2023)

Diagnostic performance of (18)F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancer
por: Rahbar, Kambiz, et al.
Publicado: (2018)

Frequency and intensity of [(18)F]-PSMA-1007 uptake after COVID-19 vaccination in clinical PET
por: Maurer, Alexander, et al.
Publicado: (2022)

Patterns of pathologic lymph nodes in anal cancer: a PET-CT-based analysis with implications for radiotherapy treatment volumes
por: Frennered, Anna, et al.
Publicado: (2021)

Comparison of [(18)F]PSMA-1007 with [(68)Ga]Ga-PSMA-11 PET/CT in Restaging of Prostate Cancer Patients with PSA Relapse
por: Hoffmann, Manuela A., et al.
Publicado: (2022)

Accuracy of standard clinical 3T prostate MRI for pelvic lymph node staging: Comparison to(68)Ga-PSMA PET-CT
por: Meißner, Sebastian, et al.
Publicado: (2019)

The value of (18)F-PSMA-1007 PET/CT in identifying non-metastatic high-risk prostate cancer
por: Hong, Jun-jie, et al.
Publicado: (2020)

Diagnostic Role of (18)F-PSMA-1007 PET/CT in Prostate Cancer Staging: A Systematic Review
por: Awenat, Salam, et al.
Publicado: (2021)

Risk of metastatic disease using [(18)F]PSMA-1007 PET/CT for primary prostate cancer staging
por: Chikatamarla, Venkata Avinash, et al.
Publicado: (2021)

An exploratory study of unexplained concentration of (18)F-PSMA-1007 in the bladder for prostate cancer PET/CT imaging
por: Dang, Jun, et al.
Publicado: (2023)

Assessment of malignancy and PSMA expression of uncertain bone foci in [(18)F]PSMA-1007 PET/CT for prostate cancer—a single-centre experience of PET-guided biopsies
por: Vollnberg, Bernd, et al.
Publicado: (2022)

Immature Plasma Cell Myeloma Mimics Metastatic Renal Cell Carcinoma on (18)F-PSMA-1007 PET/CT Due to Endothelial PSMA-Expression
por: Mittlmeier, Lena M., et al.
Publicado: (2021)

Prospective comparison of (18)F-PSMA-1007 PET/CT, whole-body MRI and CT in primary nodal staging of unfavourable intermediate- and high-risk prostate cancer
por: Malaspina, Simona, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_s2cl3hcfgrfmj7bk9t9c2mdafj